SCHEMBL30748848

SCHEMBL30748848

CNc1nc(Cl)nc2ccsc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.61
POLB P06746 2/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
GAA P10253 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
ADORA2A P29274 3/20 0.49
ADORA1 P30542 3/20 0.49
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43
TUBB2A Q13885 1/20 0.43
TUBB8 Q3ZCM7 1/20 0.43
TUBA3E Q6PEY2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24174509 1.00 HTT (0.61) HTTPOLBMEN1CYP1A2CYP3A4
SCHEMBL10268901 0.80 HTT (0.63) HTTPOLBMEN1CYP1A2CYP3A4
SCHEMBL21099859 0.80 HTT (0.63) HTTPOLBMEN1CYP1A2CYP3A4
SCHEMBL11319172 0.79 PDE7A (0.49) HTTADORA2AADORA1PDE4APDE4B
SCHEMBL22024780 0.77 IRAK4 (0.52) ADORA2AADORA1PDE4APDE4BPDE4C
SCHEMBL1284289 0.77 PDE4B (0.58) MEN1KMT2AADORA2AADORA1PDE4A
SCHEMBL55563 0.77 ADORA2A (0.58) HTTPOLBMEN1KMT2AADORA2A
SCHEMBL31462939 0.77 ADORA2A (0.58) HTTPOLBMEN1KMT2AADORA2A
SCHEMBL13840493 0.76 HTT (0.58) HTTPOLBMEN1CYP1A2CYP3A4
SCHEMBL3867946 0.76 ADORA2A (0.40) HTTADORA2AADORA1TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT HTT 78/4885POLB 683/4885MEN1 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.